Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 32Breast Neoplasms 19Head and Neck Neoplasms 16Neoplasms 11Glioblastoma 8Adenocarcinoma of Lung 8Squamous Cell Carcinoma of Head and Neck 7Colorectal Neoplasms 7Brain Neoplasms 7Adenocarcinoma, Bronchiolo-Alveolar 7Prostatic Neoplasms 6Neoplasm Metastasis 6Gliosarcoma 6Rectal Neoplasms 5Ovarian Neoplasms 5Colonic Neoplasms 5Esophageal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Respiratory Tract Diseases 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2

Interventions

relacorilant 2Mifepristone 2Corlux 2tariquidar 1pembrolizumab 1cabozantinib 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Gefitinib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adrenal Cortex Neoplasms × Gefitinib × Clear all
NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
16 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡